Method of treating a patient with a cyp3a4 substrate drug

Abstract

The present disclosure provides for methods of treating a patient with a CYP3A4 substrate drug contraindicated for concomitant administration with a strong CYP3A4 inhibitor, wherein the patient is treated with multiple doses of posaconazole, stops posaconazole treatment, and then is treated with the CYP3A4 substrate drug. In some embodiments, treatment with the CYP3A4 substrate drug is delayed for about 2-21 after stopping posaconazole. In some embodiments, the patient is treated with or prescribed a reduced dose of the CYP3A4 substrate drug for about 2-21 after stopping posaconazole.

1 .- 9 . (canceled) 
     
     
         10 . A method of treating a patient for chronic angina with ranolazine, wherein the patient is receiving treatment with posaconazole, comprising:
 (a) stopping posaconazole treatment;   (b) delaying administration of ranolazine after step (a) for up to about 7 days; then   (c) administering a dose of ranolazine that is not more than about 50% of a reference dose of ranolazine, for about 5-21 days.   
     
     
         11 . The method of  claim 10 , wherein said administration of ranolazine in step (c) is for about 5-14 days. 
     
     
         12 . The method of  claim 11 , wherein said delaying in step (b) is up to one day. 
     
     
         13 . The method of  claim 10 , wherein said administration of ranolazine in step (c) is for about 5-10 days. 
     
     
         14 . The method of  claim 13 , wherein the delay in step (b) is for up to one day. 
     
     
         15 . The method of  claim 13 , wherein the patient is not obese. 
     
     
         16 . The method of  claim 15 , wherein said administration of ranolazine in step (c) is for about 7 days. 
     
     
         17 . The method of  claim 16 , wherein said delaying in step (b) is for one day. 
     
     
         18 . The method of  claim 10 , wherein said administration of ranolazine in step (c) is for about 10-14 days. 
     
     
         19 . The method of  claim 18 , wherein the delay in step (b) is for up to one day. 
     
     
         20 . The method of  claim 18 , wherein the patient has at least one characteristic selected from the group consisting of the following:
 i) BMI of at least about 35;   ii) % IBW of at least about 150%;   iii) waist size greater than about 42 inches;   iv) % body fat greater than about 40%;   v) total body fat greater than about 40 kg, and;   vi) medically diagnosed as obese.   
     
     
         21 . The method of  claim 18 , wherein said administering of ranolazine in step (c) is for about 12 days. 
     
     
         22 . The method of  claim 21 , wherein said delaying in step (b) is for up to one day. 
     
     
         23 . The method of  claim 10 , wherein after step (c) an AUC of ranolazine is no more than about 150% of a normal baseline AUC of the ranolazine reference dose. 
     
     
         24 . The method of  claim 23 , wherein the reference dose of ranolazine is 1000 mg. 
     
     
         25 . The method of  claim 10 , wherein the reference dose of ranolazine is 1000 mg. 
     
     
         26 . The method of  claim 10 , wherein:
 the reference dose of ranolazine is 1000 mg;   said delaying in step (b) is up to one day; and   said administering of ranolazine in step (c) is for about 5-14 days.   
     
     
         27 . The method of  claim 10 , wherein:
 the reference dose of ranolazine is 1000 mg;   said delaying in step (b) is up to one day;   said administering of ranolazine in step (c) is for about 5-14 days; and   the patient has at least one characteristic selected from the group consisting of the following:   i) BMI of at least about 35;   ii) % IBW of at least about 150%;   iii) waist size greater than about 42 inches;   iv) % body fat greater than about 40%;   v) total body fat greater than about 40 kg, and;   vi) medically diagnosed as obese.